Afatinib + Prednisone for Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a combination of two drugs, afatinib and prednisone, for patients with advanced squamous non-small cell lung cancer. Afatinib aims to stop cancer growth by targeting specific proteins, while prednisone helps reduce inflammation and immune reactions. The goal is to find out if this combination is safe and effective for these patients. Afatinib has been shown to be effective as a follow-up treatment for advanced lung squamous cell carcinoma and has benefits in combination with other therapies.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop all current medications, but you cannot have had systemic glucocorticoids (a type of steroid) within 3 weeks before starting the study. It's best to discuss your specific medications with the trial team.
What makes the drug combination of Afatinib and Prednisone unique for lung cancer treatment?
Afatinib is an oral drug that irreversibly blocks certain proteins involved in cancer growth, specifically targeting mutations in the epidermal growth factor receptor (EGFR), which makes it effective for certain types of lung cancer. Prednisone is a steroid that can help reduce inflammation and manage side effects. This combination may offer a novel approach by combining targeted cancer therapy with supportive care to improve patient outcomes.12345
What data supports the effectiveness of the drugs Afatinib and Prednisone for lung cancer?
Who Is on the Research Team?
Sheena Bhalla
Principal Investigator
UT Southwestern Medical Center
Are You a Good Fit for This Trial?
Adults over 18 with advanced squamous NSCLC who've had up to three prior treatments can join. They must not have used systemic steroids recently, EGFR inhibitors, IMIDs, or anti-TNF antibodies. Participants need measurable disease per RECIST 1.1 and good organ/marrow function. No pregnant/nursing individuals or those with certain health issues like uncontrolled diabetes or symptomatic brain metastases.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Afatinib 40 mg PO daily and Prednisone 40 mg PO daily starting 7 days after Afatinib
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Afatinib
- Prednisone
Afatinib is already approved in United States, European Union, Canada, Japan for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Texas Southwestern Medical Center
Lead Sponsor